Workbook: ms-prices
Copaxon MS drug approved for tri-weekly use in Canada - The MS Wire
Takeda to Commercialize Teva MS Drug in Japan - Drug Discovery and Development
Congressmen Investigate 'Shadow Pricing' of MS Drugs | RAPS
Teva must face government's kickback claims over Copaxone - judge | Reuters
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Teva shares rise in Tel Aviv as migraine results buoy investors | The Times of Israel
Teva Charged With Paying Kickbacks to Increase Sales of MS Drug - Health Law Offices of Anthony C. Vitale
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
High-dose Copaxone the right medicine for Teva | Pharmafile
Another setback for Teva's laquinimod in MS - PMLiVE
Court refuses injunctions in pharma patent case
Teva's MS Drug Copaxone Looking for Approval in Japan - Jewish Business News
Teva fails to reclassify MS drug to thwart generics
Teva Pharmaceuticals - Wikipedia
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - España
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug | BioSpace
Multiple Sclerosis Drugs Market to Reach US$ 39,289.5 Mn by
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
